By Fineline Cube 
Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company’s Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0–87.0 billion.
Financial Highlights | Q2 2026
| Metric | Q2 2026 Result | YoY Change |
|---|---|---|
| Total Revenue | USD 22.974 billion | +48% |
| Key Products Revenue | USD 15.70 billion | +121% |
| U.S. Revenue | USD 14.4 billion | +33% |
| International Revenue | USD 8.60 billion | +80% |
| Mounjaro Sales | USD 9.90 billion | +91% |
| Zepbound U.S. Sales | USD 4.9 billion | +44% |
Therapeutic Area Performance
- Immunology, Oncology & Neuroscience: Key Products revenue grew 121% year-over-year, demonstrating exceptional momentum across Lilly’s diversified portfolio
- Diabetes & Obesity: Dominated by tirzepatide franchise, with Mounjaro and Zepbound driving unprecedented volume growth globally
- Cardiovascular: Jardiance contributed significantly to international revenue, including a USD 250 million sales-based milestone payment from the Boehringer Ingelheim collaboration
Geographic Revenue Analysis
United States
- Revenue: USD 14.4 billion (+33% YoY)
- Volume Growth: +37%, primarily driven by Zepbound and Mounjaro
- Price Impact: -3% decrease in realized prices, mainly attributed to Zepbound and Mounjaro, partially offset by rebate and discount adjustments for Trulicity, Zepbound, and Mounjaro
International Markets
- Revenue: USD 8.60 billion (+80% YoY)
- Volume Growth: +113%, led by Mounjaro
- Price Impact: -36% decrease in realized prices, primarily due to Mounjaro’s inclusion in China’s National Reimbursement Drug List (NRDL)
Product-Specific Performance
Mounjaro (tirzepatide)
- Global Sales: USD 9.90 billion (+91% YoY)
- U.S. Sales: USD 4.80 billion (+45% YoY), reflecting strong demand partially offset by lower realized prices
- International Sales: USD 5.20 billion (+172% YoY), driven primarily by volume growth
Zepbound (tirzepatide)
- U.S. Sales: USD 4.9 billion (+44% YoY), primarily driven by strong demand, partially offset by lower realized prices
- International Launch: Limited availability outside U.S. during Q2 2026
Updated Full-Year 2026 Guidance
| Metric | Updated Guidance |
|---|---|
| Total Revenue | USD 85.0–87.0 billion |
| Performance Margin | 49.0%–50.5% |
The raised guidance reflects exceptional demand for tirzepatide products, successful commercial execution, and continued momentum across Lilly’s diversified therapeutic portfolio.
Strategic Implications
- Tirzepatide Dominance: The combined Mounjaro and Zepbound franchise generated nearly USD 15 billion in Q2 revenue, establishing Lilly as the dominant player in the GLP-1/GIP dual agonist market
- Pricing Strategy: Strategic price reductions, particularly through China’s NRDL inclusion, are driving massive volume adoption while maintaining strong overall profitability
- Manufacturing Scale: Unprecedented volume growth demonstrates Lilly’s successful scaling of tirzepatide manufacturing capacity to meet global demand
- Pipeline Validation: Strong commercial performance provides financial flexibility to invest in next-generation obesity and diabetes candidates
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and business outlook. Actual results may differ materially due to competitive pressures, regulatory developments, manufacturing constraints, pricing pressures, and macroeconomic conditions.-Fineline Info & Tech